Revolutionary ulRFE® Technology Demonstrates Promising Results in Brain Cancer, Mental Health, and Pain Management Without Traditional Drugs or their Side Effects

Bellevue, WA, Oct. 28, 2025 (GLOBE NEWSWIRE) — EMulate Therapeutics, a pioneering digital therapeutics company, announces the launch of its community funding round on Wefunder (https://wefunder.com/emulatetx), enabling individual investors to participate in what could represent a fundamental transformation in how medicine is delivered.

“We’re democratizing access to an investment opportunity that could reshape modern medicine,” said Chris Rivera, EMulate Therapeutics CEO. “This community round allows everyday investors to be part of a medical breakthrough that addresses some of healthcare’s most urgent challenges, from pediatric brain cancer to the opioid crisis.”

EMulate has developed a proprietary technology that records the electromagnetic signatures of therapeutic molecules and delivers those patterns to patients through wearable devices providing therapeutic benefits without introducing chemicals into the body.

Addressing Unmet Medical Needs Across Multiple Indications

EMulate’s most advanced program targets childhood brain cancers that have seen virtually no treatment advances in decades. EMulate’s technology can potentially deliver therapeutic effects directly to brain tumors, overcoming the blood-brain barrier challenge that has made traditional chemotherapy ineffective for these conditions.

The company’s platform extends beyond oncology:

• Mental Health: Successfully emulating compounds including ketamine, psilocybin, and MDMA for treatment-resistant depression and PTSD, with potential to deliver therapeutic benefits while reducing risks associated with psychedelic therapy

• Pain Management: Demonstrating significant pain reduction in preclinical and early human studies by emulating opioids, CBD, and NSAIDs, offering a potential solution to the addiction crisis without the risks of traditional painkillers

• Broad Oncology Applications: Showing responses in over 20 tumor types through veterinary studies, with over 300 pets treated

Proven Safety and Efficacy Profile

With over 165 human patients treated across oncology trials and millions of consumer exposure hours through its commercial partner, Hapbee Technologies, EMulate’s ulRFE® technology has demonstrated:

• Zero serious adverse events attributable to the technology

• No thermal effects, ionizing radiation, or cellular toxicity

• Clinical responses observed across multiple therapeutic areas